Cargando…

Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review

Despite a good initial response to chemotherapy, the majority of patients with epithelial ovarian cancer will eventually recur and die of their disease. The introduction of targeted therapies to traditional chemotherapy regimens has done little to improve overall survival in women with ovarian cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Haller J., Straughn, J. Michael, Buchsbaum, Donald J., Arend, Rebecca C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369329/ https://www.ncbi.nlm.nih.gov/pubmed/28378010 http://dx.doi.org/10.1016/j.gore.2017.03.007

Ejemplares similares

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth
por: Turner, Taylor B, et al.
Publicado: (2017)

Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer
por: Wall, Jaclyn A., et al.
Publicado: (2020)

Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis
por: Dholakia, Jhalak, et al.
Publicado: (2021)

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2016)

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2018)

Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy
por: Bai, Huimin, et al.
Publicado: (2016)

2336 Novel PGF2a synthesis pathway in epithelial ovarian cancer
por: Hu, Muhan, et al.
Publicado: (2018)

Epigenetic Therapies as a Promising Strategy for Overcoming Chemoresistance in Epithelial Ovarian Cancer
por: Suh, Dong Hoon, et al.
Publicado: (2013)

Withaferin A ameliorates ovarian cancer-induced cachexia and proinflammatory signaling
por: Straughn, Alex R., et al.
Publicado: (2019)

Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer
por: Roane, Brandon M., et al.
Publicado: (2019)

Targeted Therapies in Epithelial Ovarian Cancer
por: Barrena Medel, Nicanor I., et al.
Publicado: (2010)

Withaferin A attenuates ovarian cancer-induced cardiac cachexia
por: Kelm, Natia Q., et al.
Publicado: (2020)

Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
por: Straughn, Alex R., et al.
Publicado: (2021)

Epigenetic therapy for ovarian cancer: promise and progress
por: Moufarrij, Sara, et al.
Publicado: (2019)

Exploiting epigenetic dependencies in ovarian cancer therapy
por: Coughlan, Aisling Y., et al.
Publicado: (2021)

Evaluation of Diagnostic Potential of Epigenetically Deregulated MiRNAs in Epithelial Ovarian Cancer
por: Kumar, Vivek, et al.
Publicado: (2021)

Antivascular Therapy for Epithelial Ovarian Cancer
por: Duhoux, Francois P., et al.
Publicado: (2010)

Targeted Therapies in Epithelial Ovarian Cancer
por: Dean, Emma, et al.
Publicado: (2010)

Epithelial ovarian cancer risk: A review of the current genetic landscape
por: Flaum, Nicola, et al.
Publicado: (2019)

Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
por: McCaw, Tyler R., et al.
Publicado: (2020)

Checkpoint inhibitors in ovarian cancer: A review of preclinical data
por: Doo, David W., et al.
Publicado: (2019)

Hormone replacement therapy and risk of epithelial ovarian cancer
por: Purdie, D M, et al.
Publicado: (1999)

SSRI use and clinical outcomes in epithelial ovarian cancer
por: Christensen, Desiré K., et al.
Publicado: (2016)

Clinical utility of targeted treatments in the management of epithelial ovarian cancer
por: Twu, Cheryl, et al.
Publicado: (2012)

The role of GRHL2 and epigenetic remodeling in epithelial–mesenchymal plasticity in ovarian cancer cells
por: Chung, Vin Yee, et al.
Publicado: (2019)

Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease
por: Arend, Rebecca C., et al.
Publicado: (2021)

Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
por: Garrido, Maritza P., et al.
Publicado: (2021)

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
por: Huang, Xu, et al.
Publicado: (2023)

Treatment of recurrent epithelial ovarian cancer
por: Pisano, Carmela, et al.
Publicado: (2009)

Treatment of Recurrent Epithelial Ovarian Cancer
por: Claussen, Carlota, et al.
Publicado: (2020)

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
por: Doo, David W., et al.
Publicado: (2020)

Publishing quality improvement outcomes in gynecologic oncology: Crucial in the pursuit of optimizing patient care
por: Michael Straughn, J.
Publicado: (2022)

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review
por: Roche, Michael, et al.
Publicado: (2018)

Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
por: Nag, Shona, et al.
Publicado: (2022)

Epithelial Ovarian Cancer: Focus on Targeted Therapy
por: Markman, M., et al.
Publicado: (2010)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer
por: Koestler, Devin C, et al.
Publicado: (2014)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments
por: Lokadasan, Rajitha, et al.
Publicado: (2016)

Clinical epidemiology of epithelial ovarian cancer in the UK
por: Doufekas, Konstantinos, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ugkrlp684mbi1rkd5rq0k51ig4